35 results about "Core protein" patented technology

The invention discloses a screening method of a protein marker combination, which is used for risk prediction of abdominal aortic aneurysm or ruptured abdominal aortic aneurysm, and optimizes the stability of a protein expression profile by constructing an initial protein expression profile; screening differential expression proteins by adopting statistical analysis, and preliminarily locking candidate proteins remarkably associated with a disease endpoint based on survival analysis or a risk regression model; performing cross validation by combining a sparse constraint algorithm and a nonlinear feature selection algorithm, and extracting a robust core marker; the independent contribution degree of each marker is evaluated through the standardized weight, and finally the optimal protein combination for disease prediction or diagnosis is determined. According to the method, six core proteins obtained through multi-algorithm cross screening can be detected in serum, multivariable logistic regression and external verification set performance both show good robustness, and an aorta protein fingerprint feature set which can be popularized and explained is formed.

The invention discloses a breast milk fat globule membrane protein simulation degree evaluation method based on multi-dimensional similarity weighted fusion, and the method comprises the steps: constructing a breast milk MFGM proteomics database, and obtaining the proteomics data of a to-be-evaluated sample; the method comprises the following steps: obtaining a reference matrix through row screening and column screening based on a breast milk MFGM proteomics database, performing logarithmic transformation on the reference matrix, calculating a mean value and a standard deviation of each feature in the reference matrix, and constructing a Z-score matrix and a missing mask matrix corresponding to the reference matrix; calculating abundance distribution similarity and missing mode similarity of the to-be-evaluated sample; setting a shrinkage coefficient based on the actual overlapping feature number, screening a core protein set according to a set threshold value, and comparing to obtain the missing MFGM protein type of the to-be-detected sample; and constructing a Top-K neighbor center, calculating the feature deviation contribution and abundance difference of the to-be-evaluated sample, and outputting key defect proteins and formula optimization suggestions according to preset feature importance indexes. And the similarity simulation accuracy is improved.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The invention relates to the technical field of organelle separation, and provides a method for rapid purification of peroxisome and oxidation regulation analysis of ultra-long chain fatty acid. The method comprises the following steps: introducing a nucleic acid sequence for coding a fusion protein into a target cell to obtain a cell material, the fusion protein comprising a truncated sequence derived from a peroxisome membrane protein and a tag sequence for affinity purification; taking the cell material as a sample, and separating the peroxisome with the fusion protein from the cell by utilizing an affinity ligand on the basis of a high affinity binding principle. Therefore, according to the method disclosed by the invention, the peroxisome can be rapidly and efficiently enriched, and the whole purification process can be completed within 30 minutes, so that the experimental period is greatly shortened; core protein components of target organelles can be efficiently reserved, and the metabolic activity of peroxisome can be maintained through a complete membrane structure and an internal environment; meanwhile, the same purified sample can synchronously support proteome and metabolome analysis, and direct association of'protein-metabolism 'data is realized.

The invention belongs to the technical field of food processing, and discloses a low-GI protein bar and a preparation method thereof. The low-GI protein bar comprises the following raw materials in parts by mass: 32-48 parts of pretreated egg white liquid, 16-24 parts of whole wheat flour, 8-12 parts of oatmeal, 5.5-8.5 parts of bamboo shoot dietary fibers, 1.5-2.5 parts of chia seeds, 7-11 parts of date palm paste, 4.5-7.5 parts of a sweetening agent and 11-17 parts of auxiliary materials, wherein a preparation method of the pretreated egg white liquid comprises the following steps: adding an acid solution into the egg white liquid to adjust the pH value to 6.5-7, and then carrying out protease enzymolysis treatment. The method effectively solves the problems that a traditional protein bar with egg white as a core protein source is obvious in fishy smell, dry, hard and rough in texture, prone to cracking and scaling in appearance and the like, and the prepared low-GI protein bar is excellent in overall sensory quality and has the nutritional characteristics of being high in protein, high in fiber and low in GI.

The application provides a nano-catalytic material system capable of targeting tumors for gene editing, which is obtained by loading a CRISPR / Cas9 plasmid of a gene editing system capable of editing a core protein gene GPX4 related to cell ferroptosis into the pores of an iron single-atom nano-catalyst, and then modifying the cell membrane of a homologous tumor. The nano-catalytic material system provided by the application has excellent Fenton catalytic performance, can accurately edit target genes, induces tumor cells to undergo ferroptosis, and has the advantages of simple synthesis process, low cost, easy batch production, high enrichment degree at a lesion site, good treatment effect, and good clinical application prospect.

The invention belongs to the field of functional food processing, and provides a preparation process of functional soybean milk powder with a sleep improving effect, which adopts a five-step linkage design of germinated soybean enzymolysis, lactobacillus plantarum fermentation, in-situ calcium nucleation, isoelectric point adsorption, exopolysaccharide stabilization and spray drying. Layered coating of the fermentation system autogenous exopolysaccharide and the fermentation modified soybean protein on the organic acid calcium microcrystal core is realized through pH gradient dynamic regulation and control, and a core-protein middle layer-polysaccharide outer layer ternary in-situ composite microcapsule structure is constructed. The multi-target synergy that the gamma-aminobutyric acid is enriched to 150-300 mg / 100 g, the isoflavone aglycone rate reaches 70-85% and the microcapsule D50 is controlled to be 5-80 microns is achieved, the three technical problems that high-solid-content low-viscosity spraying and strong interaction conflict exists, the dry powder flowability and core-shell layer stability conflict exists, and a narrow pH window and amplification tolerance are opposite are solved, and the method has wide functional food application value.

The application discloses a research method of a potential protein target point of Guangxi Yaoshan sweet tea against diabetic nephropathy based on proteomics, relates to the technical field of biological medicine, and solves the problem of lacking research on the target point of the action of Yaoshan sweet tea on the prevention and treatment of diabetic nephropathy from the perspective of proteomics. The method comprises the following steps: determining a characteristic active ingredient, namely myricetin, of Yaoshan sweet tea for intervention on diabetic nephropathy, obtaining a PPI network of network pharmacology of the intersection target point of the characteristic active ingredient of Yaoshan sweet tea and diabetic nephropathy; preparing a myricetin solution, preparing a cell disease model and grouping intervention, collecting and pre-treating a cell protein sample, performing mass spectrometry, pre-processing proteomic mass spectrometry data, screening a potential protein target point, identifying and analyzing an expression change trend of the potential protein target point, and analyzing a core protein target point and a key signal path. The application directly locates the key protein target point of Guangxi Yaoshan sweet tea on diabetic nephropathy from a protein expression level, which is more intuitive and more accurate.

The invention discloses a microcapsule nutritional feed and a preparation method thereof, and belongs to the technical field of feeds. The microcapsule nutritional feed is prepared from the following raw materials in parts by weight: 20 to 30 parts of corn, 8 to 13 parts of sorghum, 10 to 12 parts of wheat, 5 to 9 parts of soybeans, 2 to 8 parts of fish meal, 0.3 to 0.5 part of glucose, 0.3 to 0.9 part of origanum vulgare essential oil microcapsules, 2 to 4 parts of lysine, 2 to 4 parts of threonine, 2 to 4 parts of methionine, 2 to 4 parts of tryptophan and 0.3 to 0.9 part of vitamin C, the origanum vulgare essential oil microcapsule comprises a core material and a wall material, and the core material is origanum vulgare essential oil; and the wall material is chitosan modified by alpha-lipoic acid and cysteine. The raw material ratio of the microcapsule nutritional feed is scientifically designed around four dimensions of basic energy supply, core protein supplementation, functional microcapsule synergism and nutrition balance and reinforcement, the dosage of each component is highly matched with the function, and the performance of the feed is synergistically improved.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The purpose of the present invention is to provide an immunogenic composition containing a new HBV polypeptide or polynucleotides encoding the polypeptide. The immunogenic composition contains at least one polypeptide selected from among polypeptides a) through c) or polynucleotides encoding the polypeptide, and can be used for treating or preventing HBV infection. a) an HBV surface protein polypeptide including a specific amino acid substitution; b) an HBV polymerase polypeptide including an inactivated reverse transcriptase domain and an inactivated ribonuclease H domain, and including a specific amino acid substitution; and c) an HBV core protein polypeptide including a specific amino acid sequence.

The present disclosure provides, in part, 5-membered heteroaryl formamide compounds useful for disrupting HBV core protein assembly and pharmaceutical compositions thereof and methods of treating hepatitis B (HBV) infection.

The application discloses a gastric cancer biomarker composition and a screening method and application thereof, and belongs to the technical field of bioinformatics; the screening method of the gastric cancer biomarker composition comprises the following steps: collecting blood samples of gastric cancer patients and healthy controls, performing high-throughput plasma proteomics detection, and screening out differentially expressed proteins; the candidate protein markers are verified by using a prospective cohort in the UK BioSample Bank, 17 kinds of core proteins are finally determined, and the gastric cancer biomarker composition is obtained; and a gastric cancer risk prediction model is constructed by combining clinical risk factors and the protein expression levels of the gastric cancer biomarkers. The gastric cancer risk prediction model constructed by the application can realize precise stratification of gastric cancer risks, and decision curve analysis shows that the net benefit of the gastric cancer risk prediction model is significantly better than that of a traditional screening method, so that the gastric cancer risk prediction model provides an efficient tool for early warning and personalized intervention of gastric cancer.

This invention discloses an oil-dispersible color paste containing silk-core protein hydrogel, its preparation method, and its application. The oil-dispersible color paste comprises powder, oil, dispersant, and silk-core protein hydrogel. The preparation method includes: mixing the powder with oil and dispersant to obtain a semi-finished oil-dispersible color paste; adding silk-core protein hydrogel to form a mixed color paste; and then processing the mixture using a three-roll mill to obtain the finished product. When applied to liquid foundation, the oil-dispersible color paste significantly improves the smoothness, skin adhesion, fineness, waterproofness, and makeup-holding properties of the foundation. The silk-core protein hydrogel oil-dispersible color paste provided by this invention through a three-roll mill process exhibits multiple synergistic technical effects in liquid foundation compositions, solving the technical problems of poor powder dispersibility, insufficient skin adhesion, and weak makeup-holding power in existing technologies, and achieving a synergistic improvement in multiple performance aspects.

The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising at least parts of the HCV core protein, and HCV E1 and HCV E2 protein of a specific HCV strain, as well as VSV-G protein. The proteins may be assembled in rVSV-HCV particles. This has been identified to induce particularly advantageous broadly neutralizing antibodies. The invention further provides nucleic acids encoding said HCV proteins and VSV proteins but not encoding VSV-G protein. Vaccines comprising the particles, compositions or nucleic acids are disclosed as useful, in particular, for prophylactic vaccination against HCV. Methods of producing the rVSV-HCV particles or compositions of the invention and the produced particles and compositions are also subject-matter of the invention.

The invention relates to the technical field of biological medicine and food processing, and discloses a sheep bone marrow peptide composition for activating osteoblasts to be rich in bone repair factors, the sheep bone marrow peptide composition has an ordered assembly structure mediated by electrostatic adsorption, and the sheep bone marrow peptide composition is prepared from the following raw materials in parts by weight: 1000-1500 parts of sheep bone marrow peptide powder; 250 to 350 parts of sweet orange fruit powder; 450 to 700 parts of a non-denatured type II collagen protein; 800 to 1200 parts of hydrolyzed type II collagen protein; 1-10 parts of ginseng peptide powder; 1-10 parts of Chinese wolfberry fruit peptide powder; and 5 to 15 parts of stevioside. According to the invention, an interface proton buffer layer is constructed by utilizing the zwitterionic characteristics of the hydrolyzed type II collagen, and a microenvironment with high buffer capacity is formed on the surface of the non-denatured type II collagen, so that the permeation of gastric acid hydrogen ions is effectively blocked, and the local pH value of core protein is kept stable.

The invention discloses an identification method of low-temperature compost energy metabolism core protein, and belongs to the technical field of protein screening. In order to solve the problems of single screening dimension, inaccurate key protein identification and unclear mechanism analysis in the prior art, the invention provides a low-temperature compost energy metabolism core protein identification method, which comprises the following steps of: acquiring protein expression data of a low-temperature microorganism sample by utilizing a macro proteomics sequencing technology, screening differential expression proteins based on a set threshold value, and identifying a low-temperature compost energy metabolism core protein. The method comprises the following steps: identifying proteins in a significant enrichment pathway through GO function annotation and KEGG pathway enrichment analysis, carrying out importance ranking on proteins in significant enrichment related pathways by using a random forest model, screening key proteins in combination with the connectivity and network centrality of a protein interaction network, and finally identifying the energy metabolism core proteins in the low-temperature compost. The identification method provided by the invention has the advantages of strong systematicness, high screening accuracy, wide applicability and the like, and can provide key technical support for efficiency improvement and mechanism analysis of low-temperature compost.

The invention discloses application of nucleoside compounds in preparation of drugs for treating neuromuscular diseases, and belongs to the technical field of medicines. The invention discloses a novel pharmaceutical application of the nucleoside compound in preparation of drugs for treating neuromuscular diseases for the first time. Research finds that the nucleoside compound can enhance the ability of a Trmt61a / 6 compound to bind unmethylated tRNA and inhibit abnormal interaction between pathogenic mutant protein and stress particle core protein, so that peripheral nerve and muscle lesions of neuromuscular diseases and motor nerve dysfunction are improved. The invention provides a direction for new clinical application of nucleoside drugs. The invention provides possibility for preparing novel medicines for treating neuromuscular diseases.

The invention discloses an active polypeptide derived from a Seali forest virus capsid protein and application of the active polypeptide. The polypeptide is competitively combined with RNA (Ribonucleic Acid) to block the interaction between the stress particle core protein G3BP1 and the RNA, so that the formation of the stress particle is inhibited. The research finds that the 40-110 site sequence of the capsid protein is a key region for inhibiting stress particles. Even if a lysine sequence in a disordered region of the fragment is disordered, the fragment can still effectively inhibit stress particles generated by arsenite-induced U2OS cells. Further experiments show that the active polypeptide can also effectively inhibit spontaneous stress particles formed by induction of the FUS mutant, which indicates that the active polypeptide has application potential in the aspect of relieving neurodegenerative diseases.

The present application relates to the technical field of environmental purification and odor removal, and discloses a small-molecule protein environmental air disinfection and odor removal preparation and application thereof.The preparation is made of core protein components, sodium citrate, sorbitol, an anti-browning agent, L-sodium ascorbate, riboflavin, cyclodextrin or cyclodextrin derivatives, a surfactant, a preservative and deionized water, wherein the core protein components are enzymatic products with a molecular weight less than or equal to 20 kDa, and the preparation is prepared by establishing an anti-browning buffer environment, dissolving functional components, slowly adding the core protein components to make them disperse and dissolve, and finally adjusting the pH value and setting the volume.The core protein components with a molecular weight less than or equal to 20 kDa have more active sites, and can enhance the capture and combination capacity with indoor air chemical pollutants, and can act on bacterial cell structures or virus activity, so as to realize the multifunctional air purification effect of pollutant removal and biological disinfection and inactivation.

This invention discloses a total phenolic amine from bee pollen, its preparation method, and its application in alleviating zearalenone (ZEA) toxicity, belonging to the field of agricultural technology. The total phenolic amines extracted from bee pollen by this invention can reduce the bioaccumulation of ZEA and alleviate organ pathological damage; it can inhibit lipid peroxidation by activating the Nrf2 / GPX4 signaling pathway, upregulate BTB core protein, and restore the integrity of the barrier function; furthermore, TPP can regulate sex hormone balance, reverse the ZEA-induced decrease in testosterone levels and abnormal increase in estradiol, thereby comprehensively alleviating the toxic effects of ZEA.

The application discloses application of a medicine, miltefosine, in promoting bone formation and preventing and treating osteoporosis. In the bone formation process, the expression of protein phosphatase PPM1A in osteoblasts is significantly increased, the dephosphorylation of a core protein Smad2 of a TGF-beta signal path is regulated, the TGF-beta signal path is inhibited, the expression of an osteogenic marker is promoted, and the osteogenic ability of the organism is enhanced. The application discloses that the medicine, miltefosine, is used as a PPM1A enzyme activity catalyst, the in-vivo intervention of the medicine can significantly accelerate bone repair and delay bone loss of postmenopausal osteoporosis, a mechanism is that the enzyme activity of PPM1A of osteoblasts is catalyzed, the dephosphorylation of Smad2 protein is promoted, the TGF-beta / Smad2 signal path activity is inhibited, bone formation is promoted, bone repair is accelerated, and bone loss is prevented. Therefore, the miltefosine has a good application prospect in clinical treatment of promoting osteogenesis and preventing and treating osteoporosis.

This invention discloses a method for evaluating the simulation accuracy of breast milk fat globule membrane proteins (MFGMs) based on multidimensional similarity weighted fusion. The method includes: constructing a breast milk MFGM proteomics database and acquiring proteomics data of the samples to be evaluated; obtaining a reference matrix based on the breast milk MFGM proteomics database through row and column filtering, performing a logarithmic transformation on the reference matrix, calculating the mean and standard deviation of each feature in the reference matrix, and constructing a Z-score matrix and a deletion mask matrix corresponding to the reference matrix; calculating the abundance distribution similarity and deletion pattern similarity of the samples to be evaluated; setting a shrinkage coefficient based on the actual number of overlapping features, filtering a core protein set according to a set threshold, and comparing to determine the types of missing MFGM proteins in the samples to be tested; constructing Top-K neighbor centers, calculating the feature deviation contribution and abundance difference of the samples to be evaluated, and outputting key defective proteins and formulation optimization suggestions based on preset feature importance indicators. This improves the accuracy of similarity simulation.

The application discloses a monoclonal antibody or antigen-binding fragment thereof with high affinity to recognize core proteins of HCV genotype 3 and genotype 6. The amino acid sequence of the heavy chain variable region of the antibody is shown as SEQ ID NO. 1, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 5. The monoclonal antibody or antigen-binding fragment thereof can be used for qualitative and quantitative detection of hepatitis C virus core antigen (HCV cAg).

The invention relates to a multi-HBV immunogen viral vector vaccine comprising: a viral vector comprising an immunogen expression cassette, wherein the expression of a protein encoded by the expression cassette is arranged to be driven by a promoter, wherein the immunogen expression cassette encodes: a) HBV Core; b) a modified HBV polymerase (Pmut), wherein the modification is a mutation to wild-type HBV polymerase to substantially remove polymerase function; c) HBV surface antigen (HbsAg); and d) an intergenic sequence that is arranged to cause expression of at least the HBV surface antigen (HbsAg) as a separate protein from the HBV core and the modified HBV polymerase (Pmut), wherein the intergenic sequence is downstream (3′) of the sequences encoding the HBV core and the modified HBV polymerase (Pmut) and upstream (5′) of the sequence encoding the HBV surface antigen (HbsAg); and related compositions, vaccination methods and methods of treatment or prophylaxis of HBV infection.

The invention discloses a core protein loop for targeted killing of CMS2 colon cancer cells as well as a related biological material and application thereof. The invention relates to the technical field of biology, and provides a protein complex for targeted killing of CMS2 type colon cancer cells, which comprises two chimeric proteins and is a protein loop which is constructed according to abnormal activation characteristics of WNT and MYC signal pathways of the CMS2 type colon cancer cells and can be introduced into a single transcript. Experiments prove that the constructed protein loop capable of being imported through the single transcript can effectively kill the CMS2 type colon cancer cells in a targeted mode, and a safe and effective means is provided for precise targeted therapy of the CMS2 type colon cancer.

To provide nucleic acid constructs that enhance the antigen-specific immune response to hepatitis B virus. [Solution] A nucleic acid construct comprising a polynucleotide encoding one of the SNARE proteins selected from the group consisting of STX7, GOSR1, and SEC22B, and a polynucleotide encoding the core protein antigen of hepatitis B virus.

There is provided a physically stable form of Compound (I) (3 - [(8aS) - 7 - [[(4S) - 5-ethoxycarbonyl-4 - (3-fluoro-2-methyl-phenyl) - 2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl] methyl] - 3-oxo - 568, 8a - tetrahydro-imidazo [1, 5-a] pyrazin-2-yl] - 2, 2-dimethyl-propanoic acid). 1H.SOLUTION: Novel solid forms of Compound (I) are provided. Preferably, it is a solid form, which is Form D, exhibiting an X-ray powder diffraction (XRPD) pattern with characteristic peaks expressed in degrees 2 θ at 6.8 ° ± 0.2 °, 13.0 ° ± 0.2 °, 20.3 ° ± 0.2 °, 27.1 ° ± 0.2 °, 27.4 ° ± 0.2 °, 28.8 ° ± 0.2 ° and 29.1 ° ± 0.2 °.SELECTED DRAWING: None

The application discloses a set of sepsis-specific biomarkers and application thereof, and belongs to the medical detection field.The marker is composed of the combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H.Through TMT proteomics screening of serum of clinical sepsis patients, seven core proteins, APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened out.Further screening of the seven proteins in a sepsis cell model and clinical sepsis patients obtains four more important proteins, APOA1, APOH, AMBP and SERPINC1.The four proteins are verified again in a sepsis mouse animal experiment and serum of clinical sepsis patients on a large scale, and the potential of the four core proteins as serum biomarkers for early diagnosis of sepsis is determined.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a low-potassium low-phosphorus protein component for special medical purposes and a preparation method thereof. The protein component is of a liquid ready-to-use type, and comprises the following components on the basis of 100 mL of total volume: 10.0-12.0 g of separated whey protein powder; and 0.05 to 0.15 g of stevioside. 0.20 to 0.30 g of a compound stabilizer; and the balance of water. The compound stabilizer is prepared from phospholipid and xanthan gum. The separated whey protein powder with low phosphorus and potassium content and specific calcium content is selected as a core protein source, so that the final product has extremely low phosphorus-protein ratio and potassium content. The phosphorus intake brought by the product is obviously lower than that of commercially available like products, and the kidney metabolism burden and the hyperphosphatemia risk of patients are greatly relieved. The phospholipid and the xanthan gum in a specific mass ratio are used as a compound stabilizer, and the phospholipid is used as an emulsifier, so that protein particles can be effectively wrapped, and aggregation is prevented.